Note 1 - Organization

9 Months Ended

Sep. 30, 2013

Disclosure Text Block [Abstract]

Nature of Operations [Text Block]

1.     Organization

IGI Laboratories, Inc. is a Delaware corporation incorporated in 1977. The Company’s office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. The Company is a developer, manufacturer, and marketer of topical formulations. The Company’s goal is to become a leader in the generic topical pharmaceutical market. In its own label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC), and cosmetic markets. The Company’s strategy is based on three initiatives:

■ Manufacturing, developing, and marketing a portfolio of generic pharmaceutical products in its own label in topical dosage forms;

■ Increasing the Company’s current contract manufacturing and development business; and

■ Creating unique opportunities through the acquisition of additional intellectual property, and the expansion of the use of the Company’s existing intellectual property, including its licensed Novasome® technology.

In December, 2012, the Company completed implementation of its commercial infrastructure and launched its first generic topical pharmaceutical products under the IGI label. As of November 14, 2013, the Company has filed thirteen Abbreviated New Drug Applications, or ANDAs, with the United States Food and Drug Administration, or FDA to date. As discussed in Note 10, on February 1, 2013, the Company acquired product rights to econozale nitrate cream 1%. The Company is now actively marketing four IGI label products in eight presentations of those products. The remainder of product sales are under contract manufacturing agreements. The Company performs all of its product development and manufacturing at its 25,000 square foot facility in Buena, New Jersey.